On June 10, 2026, the Department of Health and Human Services Office of Inspector General (OIG) issued Advisory Opinion 26-14 (AO 26-14), another favorable advisory opinion (its fourth in as many years) involving sponsored tests.
This is part 5 of 7 in the Medicare Secondary Payer Compliance series. All titles in this series can be viewed below. Subscribe to our blog to receive these future updates. Prior installments of this series can be accessed using the links provided.
- Medicare Secondary Payer Compliance: An Introduction (Part I)
- Medicare Secondary Payer Compliance: Conditional Payments (Part II)
- Medicare Secondary Payer Compliance: Group Health Plans (Part III)
- Medicare Secondary Payer Compliance: Non-Group Health Plans (NGHPs) (Part IV)
- Medicare Secondary Payer Compliance: Providers (Part V)
by Kathleen A. Peterson, Benjamin S. Martin, Wendy C. Goldstein, and Constance A. Wilkinson
This issue of Implementing Health & Insurance Reform summarizes and discusses some issues raised by the proposed rule ("Proposed Rule") that the Centers for Medicare & Medicaid Services ("CMS") published on February 2, 2012, to implement changes to the Medicaid Drug Rebate Program ("MDRP") and to reimbursement limits for outpatient drugs covered by Medicaid.
In Part 1, we discuss proposals relating to the MDRP that would change the manner in which pharmaceutical manufacturers calculate ...
Blog Editors
Recent Updates
- The Future of 340B: New Bills Offer Competing Solutions to Modernize the 340B Drug Discount Program
- "Enough is Enough": HHS-OIG Freezes Funds for New York Medicaid Fraud Control Unit, Effective July 1
- Straight From the Source: AHLA Annual Meeting Highlights Fraud and Abuse Enforcement Efforts in 2026 and Beyond
- At the Half: No Free Kicks in FDA’s 2026 Enforcement
- CMS Codifies Drug Price Negotiation Program—With Modifications for 2029